11 Nov 2022 , 02:55 PM
Net profit of Alembic Pharmaceuticals declined 18.68% to Rs 133.35 crore in the quarter ended September 2022 as against Rs 163.99 crore during the previous quarter ended September 2021. Sales rose 14.14% to Rs 1475.01 crore in the quarter ended September 2022 as against Rs 1292.32 crore during the previous quarter ended September 2021.
| Particulars | Quarter Ended | ||
| ? | Sep. 2022 | Sep. 2021 | % Var. |
| Sales | 1475.01 | 1292.32 | 14 |
| OPM % | 15.78 | 18.46 | – |
| PBDT | 220.66 | 254.85 | -13 |
| PBT | 152.96 | 200.25 | -24 |
| NP | 133.35 | 163.99 | -19 |
Powered by Capital Market – Live News
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
